Driven by Science Inspired by Hope - Corporate Highlights October | 2019 - cloudfront.net
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
Driven by Science Inspired by Hope Corporate Highlights October | 2019
Forward-Looking Statements
This presentation may include forward-looking statements made pursuant to the Private Securities Litigation
Reform Act of 1995. Forward-looking statements are statements that are not historical facts. Such forward-looking
statements are subject to significant risks and uncertainties that are subject to change based on various factors
(many of which are beyond Cerecor’s control), which could cause actual results to differ from the forward-looking
statements. Such statements may include, without limitation, statements with respect to Cerecor’s plans,
objectives, projections, expectations and intentions and other statements identified by words such as “projects,”
“may,” “will,” “could,” “would,” “should,” “continue,” “seeks,” “aims,” “predicts,” “believes,” “expects,”
“anticipates,” “estimates,” “intends,” “plans,” “potential,” or similar expressions (including their use in the
negative), or by discussions of future matters such as: our 2019 outlook; the development of product candidates;
timing and success of trial results and regulatory review (including as it may be impacted by government shut-
downs); potential attributes and benefits of product candidates; the expansion of Cerecor’s drug portfolio; and
other statements that are not historical.
These statements are based upon the current beliefs and expectations of Cerecor’s management but are subject
to significant risks and uncertainties, including: reliance on and the need to attract, integrate and retain key
personnel; drug development costs, timing and other risks; Cerecor’s cash position and the potential need for it to
raise additional capital; risks associated with acquisitions, including the need to quickly and successfully integrate
acquired assets and personnel; and those other risks detailed in Cerecor’s filings with the Securities and Exchange
Commission. Actual results may differ from those set forth in the forward-looking statements. Except as required
by applicable law, Cerecor expressly disclaims any obligations or undertaking to release publicly any updates or
revisions to any forward-looking statements contained herein to reflect any change in Cerecor’s expectations with
respect thereto or any change in events, conditions or circumstances on which any statement is based.
2|
Overview
1 Cerecor Transformation
2 Cerecor Today
3 Orphan & Neurological Pipeline
4 Financial Highlights
5 Strategic Growth Plans and Outlook
3|
The New Cerecor
Creating Near-Term Shareholder Value
• 3 Completed
Phase I Trials CERC-800s 505(b)(2)
3
Clinical-Stage programs for CDGS
• Proof-of-Concept Fast-to-Market
Biotech Programs • NDA submissions in
in patients
next 12 to 18 months
• 2 Fast-Track
Designations
CERC-800s granted
Novel 3 RPDD from FDA
• CERC-301 in OH • Market value
Neurological PRV-eligible
• CERC-406 in PD Pipeline Programs approximately
$300M
($80 to $130M)*
RPDD = Rare Pediatric Disease Designation
4| Last 5 individual PRV’s sold between $80M and $130M; 2017 thru 2019
Management Team
Extensive Experience in Development and Commercialization
30+ years industry experience 20+ years industry experience
• President and CEO of Chelsea • V.P. Global CMC & Development, Sucampo
Therapeutics Pharmaceuticals
Dr. Simon • Chief Business and Strategy Officer, Dr. Pericles • CSO, Pharming Group
Pedder Proprietary Products at Athenex Calias • Sr. Director Rare CNS Diseases and Device
• Vice President of Oncology Pharma Lead, Shire plc
Executive Business at Hoffmann-LaRoche Chief
• Sr. Director Drug Delivery and Chemistry,
Chairman of the Scientific Officer
• Franchise Head of Hepatitis at Eyetech Pharmaceuticals
Board & Head of R&D
Hoffmann-LaRoche • Ph.D., Tufts University, Bioorganic
• Faculty Department of Pharmacology Chemistry
College of Medicine, University of
Saskatchewan
20+ years industry experience 25+ years industry experience
• Vice President of Finance, Sucampo • Sr. Vice President | Principal
Pharmaceuticals The NSCI Group
Joseph • Senior Director of Accounting, Qiagen James A. • General Manager Specialty
Miller • Chief Financial Officer, Eppendorf 5Prime Harrell Pharmaceuticals, Covidien
• Certified Public Accountant Chief • Vice President Marketing Pediatric
Chief Infectious Disease, MedImmune
Commercial
Financial Officer
Officer • Sr. Director Marketing IMIDs, Centocor a
J&J Company
• Product Manager & Hospital Specialist,
ATOD Rhone Poulenc Rorer
5|
Transforming Cerecor to Deliver Shareholder Value
Three Expected Orphan Disease Product Launches Within the Next Three Years
a Neurological Pipeline in Markets of Substantial Size and Unmet Need
2017 2018 2019
2016
CERC-301
misses
primary Acquisition Acquisition Pipeline Progression
endpoint
in Phase II TRx Pharma Avadel (AVDL) CERC-301 IP extended to 2035,
in Major (Zylera) Pediatric assets positive Phase I PoC in nOH
Depressive
Disorder CERC-800s receive ODD
CERC-801 & 802 receive FTD,
completed Phase I in HVs
Out-license Acquisition Asset Divestiture
CERC- 501 licensed to Ichorion CERC-611 out-licensed to
Janssen Rare Disease Pipeline ES Therapeutics
Pediatric Commercial
Pipeline Progression Portfolio sold for > $43M in
total value
CERC-301 re-purposed
in Orthostatic Hypotension
CERC-800s receive RPDD
6|
Recent Transaction Strengthens Balance Sheet
Sale of Pediatric Portfolio Extends Financial Runway and Provides Non-Dilutive
Financing for R&D
Cerecor Transaction Highlights
• Overall deal valued in excess of $43M
– Composite of $17M in cash and preferred stock ($4.5M in cash & 12.5M of AYTU stock)
• Assumption of Cerecor’s outstanding payment obligations payable to Deerfield CSF,
LLC (“Deerfield Note”) and other liabilities in excess of $15 million
• Elimination of existing royalty obligations & various commercial accruals of $11 million
• The Pediatric Portfolio includes the following five product lines: Aciphex® Sprinkle™,
Cefaclor for Oral Suspension, Karbinal® ER, Flexichamber™, Poly-Vi-Flor® and
Tri-Vi-Flor™
• Estimated annual expense reduction of $7 to $9 million associated with Commercial
Sales organization transfer to AYTU
• Company to fund its portfolio of development assets focusing on near-term value
drivers; including NDA submissions for CERC-800s and the expansion of the CERC-301
program
7|
Cerecor Today
Focused on Advancing Emerging Clinical & Early-stage Pipeline to Critical Value
Inflection Points
Pediatric Orphan Disease Pipeline Neurological Pipeline
• Substrate replacement therapies for Inborn • Novel mechanisms-of-action with clinical
Errors of Metabolism (IEMs) proof-of-concept and opportunity for strong
clinical differentiation
• Three 505(b)(2) programs granted ODD and
RPDD (PRV eligible) • Completed Phase I program demonstrating
robust and sustained BP effect in patients
• Expedited path(s) to NDA with three suffering from neurogenic Orthostatic
anticipated NDA filings in 2021 & 2022 Hypotension (nOH)
• Two completed Phase I programs with Fast • Expanding clinical development in OH
Track Designation (FTD) adjacencies of Diabetic OH (DOH) and
• CDG FIRST retrospective study ongoing Intradialytic Hypotension (IDH)
• Neurological markets with large commercial
opportunity & significant unmet needs
8|
Emerging Clinical & Early-Stage Pipeline
Mechanism Lead
Program Development Stage
of Action Indication
D-Galactose
CERC-801 PGM1-CDG Phase 1 Complete 505(b)(2)
replacement
Metabolic Disorders
D-Mannose
CERC-802 MPI-CDG Phase 1 Complete 505(b)(2)
replacement
L-Fucose
CERC-803 SLC35C1-CDG IND-Enabling 505(b)(2)
replacement
Nucleoside DGUOK
CERC-913 Pre-Clinical
replacement Deficiency
NMDA receptor Orthostatic
CERC-301
Neurology
Phase 1 Complete in nOH
Disorders
antagonist Hypotension
CNS-targeted Parkinson’s
CERC-406 Pre-Clinical
COMT inhibitor Disease
Denotes Pediatric Program and Expedited 505(b)(2) Approval Pathway
Denotes Pediatric Program
Denotes Neurology Program
9|
Pipeline Provides Strategic Optionality
World-Wide Estimated Patient Populations
Clinical
240M
Develop Internally & Proof-of-Concept
185M
Commercialize Independently OH >65 Toward Strategic
Partnership
Orphan
Pediatric Diseases Larger CNS
Indications
50M
Diabetic
OH
1.9M
2.9M
SCI OH
1.7M
500 500 nOH
250 50 655k
IDH
CERC-801 CERC-802 CERC-803 CERC-913 CERC-301 CERC-406
PGM1-CDG MPI-CDG SLC35C1-CDG DGUOK Orthostatic Parkinson’s
Deficiency Hypotension Disease
10| IDH = Intra-Dialytic Hypotension; nOH = Neurogenic Orthostatic Hypotension; SCI = Spinal Cord Injury; DM = Diabetes MellitusR&D Milestones
Multiple Potential Value-Generating Inflection Points Over Next 12 to 18 Months
Program Target Indication Upcoming Milestone
FDA Meeting Request YE19
CERC-801* PGM1-CDG
Targeted NDA Submission 2021
Metabolic
Disorders
FDA Meeting Request 1H20
CERC-802* MPI-CDG
Targeted NDA Submission 2021
IND Filing 2020
CERC-803* SLC35C1-CDG
Targeted NDA Submission 2022
Initiate Proof-of-Concept in
CERC-301 Orthostatic Hypotension Additional Indication(s) YE19
Neurology
Disorders
Initiate Phase II 2020
CERC-406 Parkinson’s Disease IND Filing 2020
11| *505(b)(2) PathwayPediatric Orphan Disease Portfolio CERC-800s CERC-913
Congenital Disorders of Glycosylation (CDG)
Genetic Diseases that Result in Impaired Glycoprotein Production and Function,
but are Treatable with Substrate Replacement Therapy
Glycosylation is essential for protein Factor XI
structure & function, particularly for Thrombin
circulating proteins and enzymes such Liver enzymes
as hormones and coagulation factors Hemoglobin
Some CDG patients lack the ability to
effectively utilize monosaccharide Normal Glycosylation
3
Pattern
substrates for glycoprotein synthesis
due to a single enzyme defect
Substrate replacement with
monosaccharides can compensate for Substrate replacement
2
w/ oral monosaccharides
enzyme deficiencies
Treatment with oral monosaccharides
results in improvement in serum
biomarkers of glycosylation, which can
correlate with clinical benefit Glycosylation Deficiency
1
due to CDG
13|CERC-800s
Substrate Replacement Therapies for CDGs
Monogenic Disorders Resulting in Glycoprotein Defects with Broad Clinical Spectrum,
Including Life-threatening Complications
Multi-system disease manifestation in PGM1-CDG
CERC-801 D-Galactose leads to significant improvement in key clinical symptoms
Life-threatening gastrointestinal disorder in MPI-CDG
CERC-802 D-Mannose rapidly resolves hematological & intestinal abnormalities
Immunodeficiency with CNS impairment in SLC35C1-CDG
CERC-803 L-Fucose normalizes cell counts & reduces infection risk
Ultra-orphan IEMs with Serious and Life-threatening Medical Needs
• Symptoms evidenced by serum •CERC-800s
Substrate Replacement Therapies for CDGs
Oral, Small Molecule, Naturally Occurring Monosaccharides Used as Standards-of-care
for CDGs
• Rapid onset of action
• Safe and well-tolerated
• Symptoms return upon
treatment withdrawal
D-Galactose D-Mannose L-Fucose
Eligibility CERC-801 CERC-802 CERC-803
505(b)(2) NDA Pathway ✓ ✓ ✓
NCE 5-yrs Exclusivity ✓ ✓ ✓
FDA ODD 7-yrs Exclusivity ✓ ✓ ✓
EMA ODD 10-yrs Exclusivity ✓ ✓ ✓
Priority Review Voucher ✓ ✓ ✓
15|The Value of a Priority Review Voucher
Recent PRV Sales with Purchase Amount (in millions)
The Mean purchase price over
the past 5 years has been $140M
$200
The Median purchase price over
the past 5 years has been $125M
$125 $130 $125 $130
$110 $105
$81 $80
2016 2016 2017 2017 2017 2017 2018 2018 2019
16| Reference: https://priorityreviewvoucher.org/ downloaded April 24, 2019CDG FIRST: Cerecor-Initiated Retrospective Study in CDG
Retrospective Chart Reviews & Registry Data Have Been Successfully Used to Minimize
or Obviate Prospective Clinical Studies
Developer Therapeutic (Indication) Pivotal Study Strategy
Retrospective case series summary (13/23 patients
Carbaglu
with complete data) & 3 patients treated
(NAGS Deficiency)
prospectively (2010)
Case report form from retrospective chart review of
Cholbam
patients in open-label, single-arm Expanded Access
(Bile Acid Disorders) Protocol (2015)
Retrospective case reports from a multicenter chart
ProVay Blue
review in addition to cases found in published
(Acquired Methemoglobinemia)
literature (2016)
Expanded label (from 10 mutations to 33) based on
Kalydeco
registry data & mechanistic information from lab
(Cystic Fibrosis) studies (2017)
Reference to survival data from an international
Lumizyme
registry of infantile-onset disease demonstrating
(Pompe Disease)
mortality benefit (2010)
CDG Connect Patient Insights Network (PIN)
https://connect.invitae.com/org/cdg
17|CDG FIRST Global Site Selection & Recruitment
Multi-center, International, Non-interventional, Retrospective Study of CDG Patients to
Collect Natural History and Treatment-related Data
North America Europe
Cerecor plans to leverage data from CDG FIRST Trial and other sponsor-initiated
studies to accelerate development and approval under the 505(b)(2) pathway,
with our targeted NDA filing for CERC-801 in 2021
CDG Connect Patient Insights Network (PIN)
https://connect.invitae.com/org/cdg
18|Key CERC-800s Milestones
Multiple Potential Value-Generating Inflection Points Over Next 12 to 18 Months
• Type B Meetings with FDA to clarify path to NDA
– Briefing package expected to include data collected under CDG FIRST
– Determine if pivotal study requirement and/or design
Program Target Indication Upcoming Milestone
• Type B Meeting 2020
CERC-801
PGM1-CDG • BTD Request 2020
(D-Galactose)
• NDA Submission 2021
505(b)(2) NCEs
• Type B Meeting 2020
CERC-802 MPI-CDG • BTD Request 2020
(D-Mannose)
• NDA Submission 2021
• IND Filing 2020
CERC-803
SLC35C1-CDG • BTD Request 2020
(L-Fucose)
• NDA Submission 2022
19| BTD = Break Through Therapy DesignationDeoxyguanosine Kinase (DGUOK) Deficiency
Ultra-rare, Inborn Error of Metabolism Due to Loss-of-function Mutations in DGUOK
• Inability to produce deoxyguanosine monophosphate (dGMP) results in depletion of
mitochondrial DNA (mtDNA), leading to organ dysfunction
• Most frequently mutated gene in patients with early hepatocerebral mtDNA depletion
syndrome; estimated prevalence of 1 in 500,000
• Severe depletion (>90%) of mtDNA relative to healthy individuals
• Two forms: neonatal multisystem disorder that presents in early infancy and isolated
hepatic disorder that presents later in infancy or childhood
• Liver involvement is the most prominent feature, leading to liver cirrhosis and causing
early-onset liver failure
• Liver transplant can benefit patients with isolated hepatic disease, but less so for
patients with moderate to severe neurological symptoms
• 5-Year Overall SurvivalCERC-913
dGMP ProTide for DGUOK Deficiency
Overcome Key Limitations of Direct Substrate Replacement
• The ProTide nucleotide offers plasma stability, improved permeability and
intracellular activation
dGMP
Unstable in Plasma
Poor Permeability
Phenotypic
Rescue
CERC-913
Stable in Plasma
Good Permeability
21|Neurological Disorders CERC-301 CERC-406
Orthostatic Hypotension (OH)
Autonomic Nervous System Fails to Regulate Vasoconstriction Due to Underlying
Neurological Disease
Rapid and Significant (20mm Hg) Drop in Systolic Blood Pressure (SBP)
Induced by Postural Change
• Increased risk of falls or injury, leading to decreased quality of life
• Estimated approximately 300k patients in U.S. and 1.5mm WW
Two FDA-Approved Therapies, Northera® (droxidopa) & Midodrine
Northera® Midodrine
• Norepinephrine pro-drug acting upon • Vasoconstrictor / Hypertensive Agent
adrenergic receptors • α-adrenergic receptor agonist producing an increase
• Effectiveness beyond 2 weeks of treatment in vascular tone and elevation of blood pressure
has not been established • Pro-drug with half-life ~25 minutes
• High rate (>1/3) of non-responders • Dosing Q6 to Q8 Daily
• Estimated 40K TRx Annually in the US Jun’19-Jul’18 • Estimated 1.6M TRx Annually in the US Jun’19-Jul’18
• Estimated Gross $349M Jun19-Jul’18 • Estimated Gross $457M in Annual Sales Jun’19-Jul’18
CERC-301 (Formerly Known as MK-0657)
• Established safety profile in ~400 patients and healthy volunteers
• Several studies demonstrated rapid and sustained increase in SBP without an increase
in heart rate
23|Phase I Study Design in PD Patients with nOH
Opportunity to Efficiently Demonstrate Proof-of-concept in Patients
Phase I SAD in PD Patients with nOH Visit 1 Visit 2 Visit 3 Visit 4 Visit 5a
Enrollment • 12 active centers in US Arm 1 pbo 8 mg 12 mg 16 mg 20 mg
(n = 5)
• N = 20 (8, 12, 16 & 20 mg)
Arm 2
• Double-blind, randomized, 8 mg pbo 12 mg 16 mg 20 mg
Design (n = 5)
pbo-controlled
• Interim Analysis at 10 patients Arm 3
8 mg 12 mg pbo 16 mg 20 mg
(n = 5)
• Safety, Tolerability & PK
Endpoints • BP measurement Arm 4
8 mg 12 mg 16 mg pbo 20 mg
• Symptomatic assessment (n = 5)
• 5 visits (7 to 10 days apart), 4 single escalating doses of CERC-301 or placebo
• Assess safety, tolerability & pharmacokinetics
• Measure BP effects during orthostatic standing test (OST) pre- and post-dose
• Symptomatic assessment (OHSA Item #1) at each visit
24| a Randomized 4:1CERC-301 Improves Blood Pressure Upon Standing
20mg dose results in +29.8mm Hg increase in standing SBP over placebo at 6-hour post-
dose during an Orthostatic Sanding Test
20mg vs Placebo
pre-dose vs 6-hours post-dose
155 Semi-Supine Standing
+29.8
SBP (mm Hg)
135
115
CERC-301 reduces the
magnitude of SBP drop
following an OST
95
SBP SBP SBP SBP SBP SBP SBP SBP
Seated -10 mins -5 mins Imed Prior +1 min +3 min +5 mins Seated
Placebo - PD 20 mg - PD Placebo - 6hr 20 mg - 6 Hr
25|CERC-301 PK Data
Consistent and Predictable Pharmacokinetic Profile Across All Doses Studied
CERC-301 Plasma Concentrations
450
400
350
300
250
8 mg
ng/Ml
200 12 mg
16 mg
150 20 mg
100
50
0
0 0.5 1 2 4 6
-50
Nominal Time in Hours
26|Positive Phase I Data in nOH
Final Phase l Results Depict a Rapid, Robust and Durable Increases in SBP
in PD Patients with nOH
• All doses demonstrated clinically meaningful increases in SBP over placebo within the
6-hour post-dose timepoints
– 20mg dose demonstrated a 15.2 mm Hg increase in SBP from baseline at 1-hour post-dose,
which improved to 29.1 mm Hg from baseline at 4 hours
– Early and sustained effect may differentiate CERC-301 from existing nOH / OH treatments
• All doses tested were safe and well-tolerated with no serious adverse events
• Opportunity to develop CERC-301 for additional indications characterized by
hypotension (i.e. diabetics, hemodialysis, elderly populations)
– Northera® limited to norepinephrine-deficient patient population(s)
– CERC-301’s mechanism-of-action is potentially more broadly applicable
– Initiate additional proof-of-concept study in OH population(s) by YE19
27|CERC-301: A Pipeline Within a Product
CERC-301’s Differentiated Profile Expands Addressable Patient Population to Additional
Diseases Characterized by Low Blood Pressure
Neurogenic Orthostatic Diabetic Orthostatic Intradialytic Hypotension
Hypotension Hypotension (IDH)
Estimated Patient Population Estimated Patient Population Estimated Patient Population
46.2M
3.0M
1.5M
220K 250K 405K
US ROW US ROW US ROW
Phase I Demonstrated Rapid, Initiating Phase I in Patients Initiating Phase II in Patients
Robust & Sustained BP Effect by YE 2019 in 2020
in Patients
• Large target addressable markets with limited therapeutic options
– Northera® and midodrine act as direct adrenergic agonists with narrow clinical utility, resulting
in unmet medical needs
– Clinical proof-of-concept throughout 2019 and 2020 will create an opportunity for strategic
partnership(s)
28| Population estimates at mean values from the literaturePhase I Study Design in Diabetic OH
Further Assess Durability of BP Effect to Facilitate Phase 2 Study Design
OST Performed @ 1, 2, 4 , 6, 12 and 24
Phase I Single Dose Study in Diabetic OH Hours Post-dose
Enrollment • N = 10, single center Postural Change
• Single 20 mg dose or placebo Supine Standing
Design • Double-blind, randomized, -10 -5 0 +1 +3 +5
two-way crossover min min min min min min
X X X X X X
• Safety (HbA1c monitoring )
• Tolerability & PK
Endpoints X = measure systolic/diastolic blood
• BP measurement
• Symptomatic assessment pressure and heart rate
• 2 visits (7 to 10 days apart), single 20mg dose of CERC-301 or placebo
• Assess safety, tolerability & pharmacokinetics
• Measure BP effects before and after an OST for up to 24 hours post-dose
• Symptomatic assessment (OHSA Item #1) at each visit
29| a Randomized 4:1Phase 2 Study Design in Intradialytic Hypotension
Well-defined Clinical Setting Facilitates Recruitment, Shared Opportunity for
Hemodialysis (HD) Centers with Expected Study Start in 2020
• Clinical Endpoint: change in the Number of Hypotension-induced Interventions During
Hemodialysis (HD) Sessions
N = 75
12mg /20mg 301 Group A
Randomization
End of Study
2-week lead-in baseline 12mg/20mg 301 Group B
evaluation period
A = dose 1 hour prior to HD
B = dose 2 hours prior to HD
Placebo Group
4-week treatment period
Week 1 Week 2 Week 3 Week 4 Week 5 Week 6
12 Week Study Duration with Hemodialysis 3x / week (18 sessions)
30| a Randomized 4:1CERC-406
COMT inhibitor for Parkinson’s Disease
Highly-Selective with Greater CNS Permeability for Potentially Improved Efficacy
• COMT regulates dopamine (levodopa) breakdown via the conversion of
dihydroxyphenyl-acetic acid (DOPAC) to homovanillic acid (HVA)
1st Gen COMT Drawbacks / CSF Biomarkers:
Inhibitors Marketing Status Single, 100 mg/kg CERC-406 Dose in Rats
DOPAC HVA
black box warning
Tolcapone 300 120
generic
250 100
DOPAC (% of Control)
**
HVA (% of Control)
peripherally- 200 80
Entacapone restricted
150 60
generic
100 40
**
peripherally- 50 20
Opicapone restricted
NDA Filed 7/19 0 0
Veh CERC-406 Veh CERC-406
31|Key Financial Information
Financial and Investor Information
Key Financial Indicators as of October 3, 2019 (Subject to Change)
Stock Information Investor Information
• Founded January 31, 2011 • 44.1M Shares Outstanding
• NASDAQ listed CERC • Analyst Coverage (12 month target price)
• IPO – October 16, 2016 – Michael Higgins Ladenburg Thalmann ($9.00)
– Jason McCarthy Maxim ($10.00)
• Initiated at $6.50
– Ram Selvaraju HC Wainwright ($11.00)
– 4M Units @ $6.50 for $26M
• Added to Russell 3000 Index July 1, 2019
• Stock Range (52 weeks 10/3/19)
– 52 week high $7.66 Financial Information
– 52 week low $2.71
• Cash Position June 30, 2019 = ~$10M
• Average Volume 80,390
• Ongoing Revenue from Millipred®
• Market Cap in excess of $130M – Estimated 2019 Gross Margin of $5–$6M
– Provides Strategic Optionality
33|2019 Growth Plans
Recent Events Increase Shareholder Value by Strengthening Balance Sheet to Prioritize
Pipeline Development
1 2 3
Advance Accelerate Business
Commercial Readiness
Pipeline Development Activity
Advance CERC-800s to Build commercial footprint for Out-license or partner
NDA filings and launch pediatric orphan disease in indications and/or
preparation for 2021 launch geographies
Provide further clinical
proof-of-concept in Increase market knowledge Acquire/in-license
adjacencies for CERC-301 and and insights for pricing / complimentary
initiate Phase 2 program reimbursement and pipeline assets
distribution strategies
Advance CERC-406 and CERC-
913 into Phase I studies Develop go-to-market strategy
for CERC-800s
34|Driven by Science Inspired by Hope NASDAQ:CERC www.cerecor.com
You can also read
